Literature DB >> 15203893

Validation of the transferrin receptor for drug targeting to brain capillary endothelial cells in vitro.

Corine C Visser1, Sanja Stevanović, L Heleen Voorwinden, Pieter J Gaillard, Daan J A Crommelin, Meindert Danhof, Albertus G De Boer.   

Abstract

Recently, we have shown that transferrin (Tf) is actively endocytosed by the Tf R on primary cultured bovine brain capillary endothelial cells (BCEC). The objective of this investigation is to determine whether the Tf R can facilitate endocytosis of a (protein) model drug, using Tf as a targeting vector. Secondly, the mechanism of endocytosis was investigated. Horseradish peroxidase (HRP, 40 kDa) was chosen as a model drug, since it normally does not cross the blood-brain barrier (BBB) and its concentration in biological media can be easily quantified. Tf-HRP conjugates (1:1) are actively and specifically endocytosed by BCEC in vitro in a concentration and time-dependent manner. At an applied concentration of 3 microg/ml, association (a combination of binding and endocytosis) of Tf-HRP reached equilibrium at a concentration of 2 ng/mg cell protein after 1 h of incubation at 37 degree C. This was approximately 3-fold higher compared to binding at 4 degree C (0.6 ng/mg cell protein). Association of Tf-HRP was compared to BSA-HRP. After 2 h of incubation at 37 degree C association levels were 5.2 and 2.5 ng/mg cell protein, for Tf-HRP and BSA-HRP, respectively. Under those conditions, association of Tf-HRP could be inhibited to approximately 30% of total association by an excess of non-conjugated Tf, but not with BSA, while association of BSA-HRP could be inhibited by both proteins. Furthermore, by using specific inhibitors of endocytotic processes, it was shown that association of Tf-HRP is via clathrin-coated vesicles. Association of Tf-HRP is inhibited by phenylarsine oxide (an inhibitor of clathrin-mediated endocytosis) to 0.4 ng/mg cell protein, but not by indomethacin, which inhibits formation of caveolae. Finally, following iron scavenging by deferoxamine mesylate (DFO, resulting in a higher Tf R expression) a 5-fold increase in association of Tf-HRP to 15.8 ng/mg cell protein was observed. In conclusion, the Tf R is potentially suitable for targeting of a (protein) cargo to the BBB and to facilitate its endocytosis by the BCEC.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15203893     DOI: 10.1080/10611860410001701706

Source DB:  PubMed          Journal:  J Drug Target        ISSN: 1026-7158            Impact factor:   5.121


  23 in total

1.  Comparison of albumin uptake in rat alveolar type II and type I-like epithelial cells in primary culture.

Authors:  Mika Ikehata; Ryoko Yumoto; Kosuke Nakamura; Junya Nagai; Mikihisa Takano
Journal:  Pharm Res       Date:  2007-09-11       Impact factor: 4.200

2.  Diphtheria toxin mutant CRM197-mediated transcytosis across blood-brain barrier in vitro.

Authors:  Ping Wang; Yixue Xue; Xiuli Shang; Yunhui Liu
Journal:  Cell Mol Neurobiol       Date:  2010-01-16       Impact factor: 5.046

3.  Protein-coated corrole nanoparticles for the treatment of prostate cancer cells.

Authors:  Matan Soll; Qiu-Cheng Chen; Benny Zhitomirsky; Punnajit P Lim; John Termini; Harry B Gray; Yehuda G Assaraf; Zeev Gross
Journal:  Cell Death Discov       Date:  2020-07-28

4.  Transferrin-coated gadolinium nanoparticles as MRI contrast agent.

Authors:  Huedayi Korkusuz; Karsten Ulbrich; Katerina Welzel; Verena Koeberle; Waralee Watcharin; Ute Bahr; Valery Chernikov; Thomas Knobloch; Sabine Petersen; Frank Huebner; Hanns Ackermann; Svetlana Gelperina; Wolfgang Kromen; Renate Hammerstingl; Joerg Haupenthal; Frank Gruenwald; Jens Fiehler; Stefan Zeuzem; Joerg Kreuter; Thomas J Vogl; Albrecht Piiper
Journal:  Mol Imaging Biol       Date:  2013-04       Impact factor: 3.488

5.  Megalin mediates transepithelial albumin clearance from the alveolar space of intact rabbit lungs.

Authors:  Yasmin Buchäckert; Sebastian Rummel; Christine U Vohwinkel; Nieves M Gabrielli; Benno A Grzesik; Konstantin Mayer; Susanne Herold; Rory E Morty; Werner Seeger; István Vadász
Journal:  J Physiol       Date:  2012-07-23       Impact factor: 5.182

6.  Transferrin-conjugated, fluorescein-loaded magnetic nanoparticles for targeted delivery across the blood-brain barrier.

Authors:  Feng Yan; Ying Wang; Shenzhi He; Shuting Ku; Wei Gu; Ling Ye
Journal:  J Mater Sci Mater Med       Date:  2013-06-23       Impact factor: 3.896

Review 7.  Transferrin receptors-targeting nanocarriers for efficient targeted delivery and transcytosis of drugs into the brain tumors: a review of recent advancements and emerging trends.

Authors:  Hira Choudhury; Manisha Pandey; Pei Xin Chin; Yee Lin Phang; Jeng Yuen Cheah; Shu Chien Ooi; Kit-Kay Mak; Mallikarjuna Rao Pichika; Prashant Kesharwani; Zahid Hussain; Bapi Gorain
Journal:  Drug Deliv Transl Res       Date:  2018-10       Impact factor: 4.617

8.  Uptake of ANG1005, a novel paclitaxel derivative, through the blood-brain barrier into brain and experimental brain metastases of breast cancer.

Authors:  Fancy C Thomas; Kunal Taskar; Vinay Rudraraju; Satyanarayana Goda; Helen R Thorsheim; Julie A Gaasch; Rajendar K Mittapalli; Diane Palmieri; Patricia S Steeg; Paul R Lockman; Quentin R Smith
Journal:  Pharm Res       Date:  2009-09-23       Impact factor: 4.200

9.  Translocation of the insulin-regulated aminopeptidase to the cell surface: detection by radioligand binding.

Authors:  H Demaegdt; L Smitz; J-P De Backer; M T Le; M Bauwens; E Szemenyei; G Tóth; Y Michotte; P Vanderheyden; G Vauquelin
Journal:  Br J Pharmacol       Date:  2008-04-21       Impact factor: 8.739

Review 10.  Development of Polymeric Nanoparticles for Blood-Brain Barrier Transfer-Strategies and Challenges.

Authors:  Weisen Zhang; Ami Mehta; Ziqiu Tong; Lars Esser; Nicolas H Voelcker
Journal:  Adv Sci (Weinh)       Date:  2021-03-07       Impact factor: 16.806

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.